Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
MedImmune LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
MedImmune LLC, Medical Devices Deals, 2011 to YTD 2017 12
MedImmune LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
MedImmune LLC, Pharmaceuticals & Healthcare, Deal Details 17
Venture Financing 17
ADC Therapeutics To Raise US$50 Million In Venture Financing 17
Partnerships 19
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 19
AstraZeneca and MedImmune Expands Agreement with Incyte 20
Ethris Enters into Research Agreement with Astrazeneca and MedImmune 21
Sanofi Enters into Co-Development Agreement with MedImmune 22
MedImmune Enters into Co-Development Agreement with Abpro 23
MedImmune Enters into Agreement with Genisphere 24
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 25
Cepheid, MedImmune and Combacte Enter into Agreement 26
Rani Therapeutics Enters into Agreement with MedImmune 27
Igenica Biotherapeutics Enters into Research Agreement with MedImmune 28
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 29
MedImmune Enters into Research Agreement with University of Sheffield 30
Vall d’Hebron Institute of Oncology Enters into Agreement with AstraZeneca 31
MedImmune Enters into Agreement with Juno Therapeutics 32
MedImmune Enters into Research Agreement with Joslin Diabetes Center 33
MedImmune Enters into Research Agreement with University of Manchester 34
MedImmune Enters into Research Agreement with COEBP 35
MedImmune Enters into Co-Development Agreement with National Cancer Institute 36
Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 37
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 38
Cancer Research UK Forms Joint Venture with MedImmune 40
Advaxis Enters into Agreement with MedImmune 41
MedImmune Enters Into Research Agreement With Cambridge University 42
Biolojic Design Enters into Partnership with MedImmune 43
MedImmune Enters Into Research Agreement With Johns Hopkins University 44
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 45
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 46
PeptiDream Enters into Drug Discovery Agreement with MedImmune 47
Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 48
Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 50
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 51
University Of Michigan Medical School Enters Into Research Agreement With MedImmune 52
AgonOx Enters Into Co-Development Agreement With MedImmune 53
Pfenex Enters Into Collaboration With MedImmune 54
MedImmune Enters Into Co-Development Agreement With Inserm Transfert 55
Licensing Agreements 56
GamaMabs Enters into Licensing Agreement with MedImmune 56
Regeneron Pharma Enters into Licensing Agreement with MedImmune 57
MedImmune Enters into Licensing Agreement with Wacker Biotech 58
MedImmune Enters into Licensing Agreement with 3M Drug Delivery Systems 59
Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 60
Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 61
MedImmune Enters into Licensing Agreement with Inovio Pharma 62
Kolltan Pharma Enters into Licensing Agreement with Spirogen 63
MedImmune To Enter Into Licensing Agreement With Pfizer 64
Sinovac Biotech Amends Licensing Agreement with MedImmune 65
Shionogi Enters into Licensing Agreement with MedImmune 66
biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 67
MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 68
Humabs Biomed Enters into Licensing Agreement with MedImmune 70
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 71
Kolltan Pharma Enters Into Licensing Agreement With MedImmune 72
Axerion Therapeutics Enters Into Licensing Agreement With MedImmune For Alzheimer’s Disease 73
Spirogen Enters Into Licensing Agreement With Genentech 74
Acquisition 75
MedImmune Acquires Definiens for USD150 Million 75
MedImmune Acquires Spirogen From Auven Therapeutics For US$440 Million 76
MedImmune Completes Acquisition Of Amplimmune For Up To US$500 Million 78
MedImmune Acquires AlphaCore Pharma, Cholesterol Drug Developer 79
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 80
MedImmune LLC – Key Competitors 81
MedImmune LLC – Key Employees 82
MedImmune LLC – Locations And Subsidiaries 83
Head Office 83
Other Locations & Subsidiaries 83
Recent Developments 85
Government and Public Interest 85
Jul 06, 2017: New Synthetic DNA-Based Strategy Shows Promise Against a Diverse Range of Influenza Viruses 85
Product News 86
11/14/2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer 86
Aug 23, 2016: IXICO and Cambridge Cluster Study to Detect Early Signs of Alzheimer’s Disease 87
07/21/2016: New Study Presents Groundbreaking Pre-clinical work in Developing Immune Therapy 88
Apr 22, 2016: AstraZeneca launches integrated genomics approach to transform drug discovery and development 89
Product Approvals 91
Mar 29, 2017: AstraZenecas potential medicine for neuromyelitis optica spectrum disorder receives orphan designation in Europe 91
Oct 27, 2016: AstraZeneca head and neck cancer trials 92
Mar 09, 2016: AstraZeneca’s potential medicine for neuromyelitis optica receives FDA Orphan Drug Designation 93
Mar 07, 2016: Medimmune receives fast track designation in the US for MEDI8852 for treatment of patients hospitalised with influenza A 94
Clinical Trials 95
Sep 26, 2017: Study Investigates Novel Immunotherapeutic Delivery Strategy for Preventing Infection with Antibiotic Resistant Bacteria 95
May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer 96
Jan 18, 2017: Novel Anti-IL-6 Antibody for Rheumatoid Arthritis from WuXi–MedImmune Joint Venture Receives Clinical Trial Permit from CFDA 97
Nov 22, 2016: AstraZeneca head and neck cancer trials resume new patient enrolment as FDA lifts partial clinical hold 98
Sep 06, 2016: Mesothelioma Treatment Center at Baylor St. Luke’s launches clinical trial of cancer combination therapy 99
Apr 15, 2016: Preliminary study: Antibody therapy reduces cancer stem cells in multiple myeloma 100
Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan 101
Feb 17, 2016: Immune-targeting drug combo shows promise for lung cancer patients, says Moffitt 102
Feb 08, 2016: Astrazeneca’S Combination Of Durvalumab With Tremelimumab Shows Clinical Activity In Non-Small Cell Lung Cancer Irrespective Of PD-L1 Status 103
Appendix 105
Methodology 105
About GlobalData 105
Contact Us 105
Disclaimer 105
MedImmune LLC, Pharmaceuticals & Healthcare, Key Facts 2
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
MedImmune LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
MedImmune LLC, Deals By Therapy Area, 2011 to YTD 2017 11
MedImmune LLC, Medical Devices Deals, 2011 to YTD 2017 12
MedImmune LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
ADC Therapeutics To Raise US$50 Million In Venture Financing 17
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 19
AstraZeneca and MedImmune Expands Agreement with Incyte 20
Ethris Enters into Research Agreement with Astrazeneca and MedImmune 21
Sanofi Enters into Co-Development Agreement with MedImmune 22
MedImmune Enters into Co-Development Agreement with Abpro 23
MedImmune Enters into Agreement with Genisphere 24
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 25
Cepheid, MedImmune and Combacte Enter into Agreement 26
Rani Therapeutics Enters into Agreement with MedImmune 27
Igenica Biotherapeutics Enters into Research Agreement with MedImmune 28
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 29
MedImmune Enters into Research Agreement with University of Sheffield 30
Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 31
MedImmune Enters into Agreement with Juno Therapeutics 32
MedImmune Enters into Research Agreement with Joslin Diabetes Center 33
MedImmune Enters into Research Agreement with University of Manchester 34
MedImmune Enters into Research Agreement with COEBP 35
MedImmune Enters into Co-Development Agreement with National Cancer Institute 36
Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 37
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 38
Cancer Research UK Forms Joint Venture with MedImmune 40
Advaxis Enters into Agreement with MedImmune 41
MedImmune Enters Into Research Agreement With Cambridge University 42
Biolojic Design Enters into Partnership with MedImmune 43
MedImmune Enters Into Research Agreement With Johns Hopkins University 44
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 45
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 46
PeptiDream Enters into Drug Discovery Agreement with MedImmune 47
Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 48
Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 50
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 51
University Of Michigan Medical School Enters Into Research Agreement With MedImmune 52
AgonOx Enters Into Co-Development Agreement With MedImmune 53
Pfenex Enters Into Collaboration With MedImmune 54
MedImmune Enters Into Co-Development Agreement With Inserm Transfert 55
GamaMabs Enters into Licensing Agreement with MedImmune 56
Regeneron Pharma Enters into Licensing Agreement with MedImmune 57
MedImmune Enters into Licensing Agreement with Wacker Biotech 58
MedImmune Enters into Licensing Agreement with 3M Drug Delivery Systems 59
Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 60
Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 61
MedImmune Enters into Licensing Agreement with Inovio Pharma 62
Kolltan Pharma Enters into Licensing Agreement with Spirogen 63
MedImmune To Enter Into Licensing Agreement With Pfizer 64
Sinovac Biotech Amends Licensing Agreement with MedImmune 65
Shionogi Enters into Licensing Agreement with MedImmune 66
biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 67
MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 68
Humabs Biomed Enters into Licensing Agreement with MedImmune 70
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 71
Kolltan Pharma Enters Into Licensing Agreement With MedImmune 72
Axerion Therapeutics Enters Into Licensing Agreement With MedImmune For Alzheimer’s Disease 73
Spirogen Enters Into Licensing Agreement With Genentech 74
MedImmune Acquires Definiens for USD150 Million 75
MedImmune Acquires Spirogen From Auven Therapeutics For US$440 Million 76
MedImmune Completes Acquisition Of Amplimmune For Up To US$500 Million 78
MedImmune Acquires AlphaCore Pharma, Cholesterol Drug Developer 79
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 80
MedImmune LLC, Key Competitors 81
MedImmune LLC, Key Employees 82
MedImmune LLC, Other Locations 83
MedImmune LLC, Subsidiaries 84